Singapore markets close in 3 hours 10 minutes
Straits Times Index
3,308.24 +8.24 (+0.25%) Nikkei
38,617.93 -15.09 (-0.04%) Hang Seng
18,078.69 -256.63 (-1.40%) FTSE 100
8,272.46 +67.35 (+0.82%) Bitcoin USD
64,545.49 -869.36 (-1.33%) CMC Crypto 200
1,353.05 -29.62 (-2.14%)
PCVX Sep 2024 70.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:18AM EDT. Market open.
| Previous close | 10.10 |
| Open | 10.60 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 70.00 |
| Expiry date | 2024-09-20 |
| Day's range | 10.10 - 10.60 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Simply Wall St.We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GuruFocus.com
Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview
Consistent with Analyst Projections Amidst Strategic Advancements
GlobeNewswireVaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen
© 2024 Yahoo. All rights reserved.